Inclusion Criteria:

- Previously untreated, histologically proven T-cell Lymphoma (any of the following):

- Peripheral T-cell lymphoma Not Otherwise Specified (PTCL NOS)

- Systemic Anaplastic large cell lymphoma (ALCL) ALK negative cases only

- Angioimmunoblastic T-cell lymphoma

- Hepatosplenic gamma/ delta T-cell lymphoma

- Bulky stage I not being considered for reduced chemotherapy plus involved field
radiotherapy or stage II, III or IV.

- Patient is male or female, and ≥18 years of age on the day of signing informed
consent.

- WHO performance status 0, 1 or 2.

- Cross sectional imaging from a baseline contrast enhanced CT should show at least one
measurable disease site that is at least 2 cm in longest diameter and measurable in
two perpendicular dimensions with or without corresponding Fluorodeoxyglucose(FDG)
avid lesions.

- Adequate cardiac function; formal assessment of left ventricular ejection fraction is
only required if clinically indicated (a baseline echocardiogram should be done for
patients with either hypertension, age > 60 years or history of cardiac disease)

- Adequate bone marrow function: absolute neutrophil count (ANC) ≥1.0x109/l; white
blood cell count ≥ 3x109/l; platelets ≥ 100x109/l; haemoglobin (Hb) ≥ 9g/dl (can be
post-transfusion), unless deemed disease related

- Adequate renal function: calculated creatinine clearance ≥50ml/minute.

- Adequate liver function: serum bilirubin ≤1.5x Upper limit of normal (ULN); Alanine
transaminase/Aspartate transaminase (ALT/AST) ≤2.5x ULN; ALP ≤3x ULN (in the absence
of liver metastases). If liver metastases are present, ALT, AST or Alkaline
phosphatase (ALP) ≤5x ULN are permitted. Isolated hyperbilirubinaemia due to
Gilbert's disease is acceptable

- Female patient of childbearing potential must have a negative serum or urine β-human
chorionic gonadotropin(hCG)pregnancy test at baseline.

- Written informed consent must be obtained prior to start of study treatments. Scans
and bone marrow biopsies performed within 4 weeks of commencement of therapy will be
acceptable provided they have been performed according to study requirements.

- Patient agreeable to use contraception for the period of study treatment and up to 12
months after the last dose of study drugs.

Exclusion Criteria:

- Documented or symptomatic central nervous system involvement or leptomeningeal
disease.

- Patients with no measurable disease on the contrast enhanced CT scan at baseline.

- Any other clinically significant disease or co-morbidity which may adversely affect
the safe delivery of treatment within this trial.

- Any other malignancies diagnosed or treated within the last 5 years (other than
curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the
cervix).

- Treatment with another investigational agent within 30 days of commencing study
treatment.

- Known positive tests for human immunodeficiency virus (HIV) infection, hepatitis C
virus, acute or active hepatitis B infection.

- Patient is pregnant or breastfeeding, or expecting to conceive or father children
within one year of finishing study treatment.

- Patients with poorly controlled diabetes mellitus

- Hypersensitivity or contraindication to any of the study drugs as stated in the
Summaries of product characteristics(SmPCs)for each of the study drugs. Patients with
previous cardiac infarct but satisfactory cardiac function may be allowed at the
discretion of Chief Investigator.